gene

IL10

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about IL10: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

541Connections

1Hypotheses

5Analyses

50Outgoing

50Incoming

1Experiments

7Debates

Summary

IL10 is a gene implicated in neurodegeneration research. Key relationships include: therapeutic target, associated with, expressed in. Associated with ALS, Als, Atherosclerosis. Connected to 210 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	IL10
Full Name	Interleukin 10
Chromosome	1q31.3
Protein Type	Ligand
Target Class	Ligand
Function	Recombinant protein replacement or monoclonal antibody modulation
Mechanism of Action	Recombinant protein replacement or monoclonal antibody modulation
Druggability	Low (0.36)
Clinical Stage	Phase II
Amino Acids	160 aa
Exons	5
Pathways	JAK-STAT pathway
UniProt ID	Q6FGW4
NCBI Gene ID	3586
GeneCards	IL10
Human Protein Atlas	IL10
Associated Diseases	Als, Alzheimer, Alzheimer's disease, Crohn'S Disease, Hypertension
Known Drugs/Compounds	Viral Therapeutic Approach
Interactions	ACE, AHR, AKT, ALZHEIMER, AMYLOID, APOPTOSIS
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Early Immune Challenge Tolerance Induction
KG Connections	541 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: IL10 — AlphaFold Q6FGW4 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

IL10 — Interleukin 10

gene · 651 words

→

Pathway Diagram

graph TD
    IL10["IL10"]
    IL10 -->|"activates"| osteoblastogenesis["osteoblastogenesis"]
    IL10 -->|"inhibits"| NEUROINFLAMMATION["NEUROINFLAMMATION"]
    IL10 -->|"inhibits"| Fibrosis["Fibrosis"]
    IL10 -->|"target for"| Ms["Ms"]
    IL10 -->|"target for"| Hepatitis["Hepatitis"]
    IL10 -->|"target for"| Carcinoma["Carcinoma"]
    IL10 -->|"target for"| Cancer["Cancer"]
    IL10 -->|"target for"| Als["Als"]
    IL10 -->|"target for"| Inflammation["Inflammation"]
    h_f9c6fa3f["h-f9c6fa3f"] -->|"target for"| IL10
    MICROGLIA["MICROGLIA"] -->|"expressed in"| IL10
    FGF20["FGF20"] -->|"target for"| IL10
    BRG1["BRG1"] -->|"target for"| IL10
    NRCAM["NRCAM"] -->|"target for"| IL10
    NOTCH2["NOTCH2"] -->|"target for"| IL10
    EP300["EP300"] -->|"target for"| IL10
    CTNNB1["CTNNB1"] -->|"target for"| IL10
    NEUROD1["NEUROD1"] -->|"target for"| IL10

Outgoing (336)

Target	Relation	Type	Str
Immune Cell Activation	inhibits	process	0.95
Cytokine Production	inhibits	process	0.95
Sphingolipid Metabolism	inhibits	pathway	0.95
M2 Microglia Phenotype	upregulates	phenotype	0.90
very long chain ceramides	suppresses	compound	0.90
osteoblastogenesis	activates	pathway	0.90
Neuroinflammation	inhibits	process	0.90
Microglia Polarization	modulates	process	0.90
SPHINGOLIPID METABOLISM	inhibits	entity	0.90
Neuroinflammation	treats	disease	0.90
Inflammatory Bowel Disease	protects_against	disease	0.90
Inflammation	inhibits	process	0.88
Immune Response	inhibits	process	0.85
Crohn'S Disease	associated_with	disease	0.85
Sphingolipid Metabolism	regulates	pathway	0.85
Crohn's Disease	risk_factor_for	disease	0.85
Dopaminergic Neuron Loss	protects_against	phenotype	0.85
innate immune cells	modulates	cell_type	0.85
Anti-Inflammatory Response	mediates	process	0.85
Parkinson's Disease	treats	disease	0.80
MACROPHAGE	regulates	entity	0.80
MICROGLIA	regulates	entity	0.80
Atherosclerosis	inhibits	disease	0.80
motor recovery	promotes	phenotype	0.80
Cancer	therapeutic_target	disease	0.75
Als	associated_with	disease	0.75
NEUROINFLAMMATION	inhibits	phenotype	0.72
AQP4-specific B cell activation	inhibits	mechanism	0.70
Immune Response	involved_in	process	0.70
Obesity	activates	disease	0.65
Pulmonary Fibrosis	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Depression	activates	disease	0.65
ALS	expressed_in	disease	0.65
Ms	associated_with	disease	0.65
Obesity	expressed_in	disease	0.65
Als	expressed_in	disease	0.65
Senescence	associated_with	disease	0.65
Depression	expressed_in	disease	0.65
Pancreatic Cancer	therapeutic_target	disease	0.65
Prostate Cancer	therapeutic_target	disease	0.65
Infection	therapeutic_target	disease	0.65
Gastric Cancer	therapeutic_target	disease	0.65
ALS	associated_with	disease	0.65
Alzheimer	associated_with	disease	0.65
Lung Cancer	therapeutic_target	disease	0.65
Inflammation	associated_with	disease	0.65
Ms	activates	disease	0.65
Epilepsy	activates	disease	0.65
Ms	therapeutic_target	disease	0.65

Incoming (205)

Source	Relation	Type	Str
Betulinic Acid	upregulates	compound	0.90
Mbdnf@Αitgev	upregulates	compound	0.90
Lipid Nanoparticle	transports	compound	0.90
Microglia	expressed_in	cell_type	0.90
h-f9c6fa3f	targets	hypothesis	0.90
CD22 Blockade	upregulates	drug	0.85
Viral Therapeutic Approach	targets	drug	0.85
RU486	upregulates	drug	0.85
Ginsenoside Ro	upregulates	compound	0.85
GINSENOSIDE_RO	upregulates	compound	0.80
mesenchymal stem cell	associated_with	cell_type	0.75
GENES	associated_with	gene	0.70
TGFB1	associated_with	gene	0.70
TNF	associated_with	gene	0.70
JUN	associated_with	gene	0.70
GENES	therapeutic_target	gene	0.70
NOS2	activates	gene	0.65
MICROGLIA	expressed_in	cell_type	0.64
PTGS2	therapeutic_target	gene	0.60
IL6	regulates	gene	0.60
MMP9	regulates	gene	0.60
APC	therapeutic_target	gene	0.60
IL6	expressed_in	gene	0.60
IL1B	expressed_in	gene	0.60
AXIN1	therapeutic_target	gene	0.60
PPARD	therapeutic_target	gene	0.60
TREM2	expressed_in	gene	0.60
CREBBP	therapeutic_target	gene	0.60
DENND1B	implicated_in	gene	0.60
ERAP2	implicated_in	gene	0.60
FUT2	implicated_in	gene	0.60
INFLAMMATION	therapeutic_target	gene	0.60
IL-6	associated_with	gene	0.60
TFCP2	associated_with	gene	0.60
FGF20	targets	gene	0.60
ABCB1	targets	gene	0.60
FZD7	targets	gene	0.60
AXIN2	targets	gene	0.60
CD44	targets	gene	0.60
ALDH1A1	targets	gene	0.60
SORL1	associated_with	gene	0.60
AKT	activates	gene	0.60
IBA1	expressed_in	gene	0.60
BACH2	implicated_in	gene	0.60
CTNNB1	therapeutic_target	gene	0.60
NEUROD1	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
FOXM1	therapeutic_target	gene	0.60
LEF1	therapeutic_target	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Early Immune Challenge Tolerance Induction	0.000	-	Neuroinflammation and microglial priming

Mentioning Analyses (5)

Scientific analyses that reference this entity

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (7)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning IL10 in their description or question text

No additional research found

IL10

Understanding Entity Pages

Summary

Wiki Pages (1)

IL10 — Interleukin 10

Pathway Diagram

Outgoing (336)

Incoming (205)

Targeting Hypotheses (1)

Mentioning Analyses (5)

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c

How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimm

Neuroinflammation and microglial priming in early Alzheimer's Disease

Digital biomarkers and AI-driven early detection of neurodegeneration

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (1)

Related Papers (0)

Debates (7)

The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper d

The title suggests B cells actively maintain tolerance to AQP4, but the specific

The title suggests B cells actively maintain tolerance to AQP4, but the specific

Investigate mechanistic links between early microglial priming states, neuroinfl

Investigate mechanistic links between early microglial priming states, neuroinfl

Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene

What are the mechanisms underlying what are the mechanisms by which gut microbio

Related Research